Huvepharma announces a new pinkeye vaccine

Huvepharma releases a conditional licensed vaccine for the prevention of pinkeye caused by Moraxella bovoculi in cattle.

Huvepharma, a fast-growing global pharmaceutical company focused on developing, manufacturing and marketing human and animal health products, announced the release of a conditional licensed vaccine for the prevention of pinkeye caused by Moraxella bovoculi in cattle.

The new Moraxella bovoculi Bacterin provides superior protection with eight specific isolates and an easily syringeable adjuvant. Pairing this bacterin with AgriLabs’ well-known vaccine, I-Site XP, for the prevention of pinkeye caused by M. bovis, veterinarians will expand cattle raisers prevention protocol for optimal coverage of this disease, the company said. Both vaccines will be supported through AgriLabs, a Huvepharma Company.

“Controlling pinkeye has always been a top concern for cattle producers which is why we’ve devoted so much effort into developing and delivering quality vaccines to combat a disease that costs the industry more than $150 million annually,” remarked Sean O’Hare, executive vice president of AgriLabs. “The addition of this conditionally licensed Moraxella bovoculi vaccine allows AgriLabs to offer a full complement of pinkeye prevention solutions to address this critical disease. Additionally, the new M. bovoculi vaccine simplifies the process for veterinarians because it is immediately available.”

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish